Literature DB >> 7978721

Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization.

J P Mullooly1, M D Bennett, M C Hornbrook, W H Barker, W W Williams, P A Patriarca, P H Rhodes.   

Abstract

OBJECTIVE: To estimate the cost-effectiveness and net medical care costs of programs for annual influenza vaccinations for the elderly in a health maintenance organization (HMO).
DESIGN: Population-based, case-control study.
SETTING: The Northwest Region of Kaiser Permanente, a prepaid group practice HMO in Portland, Oregon. PARTICIPANTS: Kaiser Permanente members 65 years of age and older who had at least 1 month of HMO eligibility during any of nine influenza seasons in the 1980s. MEASUREMENTS: The HMO's costs for providing medical care and conducting vaccination programs were estimated using accounting data.
RESULTS: 32% of high-risk elderly persons and 22% of non-high-risk elderly persons received influenza vaccinations. Aggregate vaccine effectiveness in preventing pneumonia and influenza hospitalizations was 30% (95% CI, 17% to 42%) for high-risk and 40% (CI, 1% to 64%) for non-high-risk elderly persons. The net savings to the HMO per vaccination was $6.11 for high-risk elderly persons and $1.10 for all elderly persons. The HMO incurred a net cost of $4.82 per vaccination for non-high-risk elderly persons.
CONCLUSIONS: Influenza vaccination rates in this HMO were relatively low for high-risk elderly persons. The medical care costs saved by preventing pneumonia and influenza through vaccination of high-risk elderly persons provide a compelling rationale to increase compliance with recommendations for annual influenza vaccination. Indirect benefits, such as prevention of suffering, incapacity, and lost wages, are likely to compensate for the small net cost of vaccinating non-high-risk elderly persons.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7978721     DOI: 10.7326/0003-4819-121-12-199412150-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  61 in total

1.  How to treat influenza and colds.

Authors:  M C Kim; N P Lee
Journal:  West J Med       Date:  2000-04

2.  Influenza vaccination in 29 countries. An update to 1997.

Authors:  F Ambrosch; D S Fedson
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

3.  Mass influenza vaccination in Ontario: a sensible move.

Authors:  R E Schabas
Journal:  CMAJ       Date:  2001-01-09       Impact factor: 8.262

Review 4.  Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Authors:  M J Postma; R M Baltussen; M L Heijnen; L T de Berg; J C Jager
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

5.  Effectiveness of influenza vaccination in the elderly in a community in Italy.

Authors:  E Crocetti; S Arniani; F Bordoni; G Maciocco; M Zappa; E Buiatti
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

Review 6.  Oseltamivir: a review of its use in influenza.

Authors:  K McClellan; C M Perry
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Influenza in The Netherlands.

Authors:  J A Knottnerus
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

8.  Economic evaluation of influenza vaccination and economic modelling. Can results be pooled?

Authors:  T Jefferson; V Demicheli
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

9.  Economic evaluation of influenza vaccination and economic modelling.

Authors:  M Malek
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

10.  Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.

Authors:  Pawel Grzesiowski; Raquel Aguiar-Ibáñez; Aleksandra Kobryń; Laure Durand; Pierre-Emmanuel Puig
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.